These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33076776)

  • 1. Preablation Diagnostic Whole-Body Scan vs Empiric Radioactive Iodine Ablation in Differentiated Thyroid Cancer: Cost-effectiveness Analysis.
    Arjani S; Quinn PL; Chokshi RJ
    Otolaryngol Head Neck Surg; 2021 Jun; 164(6):1172-1178. PubMed ID: 33076776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
    Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiated thyroid carcinoma: Incremental diagnostic value of
    Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
    Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease.
    Ma EZ; Kuo JH; Malek R; Turner DJ; Olson JA; Slejko JF; Mullins CD; Hu Y
    Surgery; 2023 Jan; 173(1):193-200. PubMed ID: 36208983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
    Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
    Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High thyroglobulin and negative whole-body scan: no long-term benefit of empiric radioiodine therapy.
    Tramontin MY; Nobre GM; Lopes M; Carneiro MP; Alves PAG; de Andrade FA; Vaisman F; Corbo R; Bulzico D
    Endocrine; 2021 Aug; 73(2):398-406. PubMed ID: 33570724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK; Murby B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine prophylactic central neck dissection for low-risk papillary thyroid cancer is not cost-effective.
    Garcia A; Palmer BJ; Parks NA; Liu TH
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):754-61. PubMed ID: 24862564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated thyroid cancer: lobectomy and radioiodine, a treatment suitable for all cases?
    Allan E; Owens SE; Waller ML
    Nucl Med Commun; 1999 Nov; 20(11):983-9. PubMed ID: 10572907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing radioiodine uptake after thyroid cancer surgery.
    Bai JB; Shakerian R; Westcott JD; Lichtenstein M; Miller JA
    ANZ J Surg; 2015; 85(7-8):572-7. PubMed ID: 23964714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective.
    Mernagh P; Suebwongpat A; Silverberg J; Weston A
    Value Health; 2010; 13(2):180-7. PubMed ID: 19818064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis.
    Vidal-Trecan GM; Stahl JE; Eckman MH
    Thyroid; 2004 Nov; 14(11):933-45. PubMed ID: 15671772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals.
    Vallejo JA; Muros MA
    Rev Esp Med Nucl Imagen Mol; 2017; 36(6):362-370. PubMed ID: 28539216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
    Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
    Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
    Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.
    Kim EY; Kim TY; Kim WG; Yim JH; Han JM; Ryu JS; Hong SJ; Yoon JH; Gong G; Kim WB; Shong YK
    Nucl Med Commun; 2011 Oct; 32(10):954-9. PubMed ID: 21849927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.